Biosimilar breast cancer drug trial ends early
Disease control
Terminated
This study tested a new biosimilar drug (PERT-IJS) against the approved drug Perjeta for people with a certain type of breast cancer (HER2-positive, hormone receptor-negative) that had not spread far. The goal was to see if the biosimilar worked as well at shrinking tumors before…
Phase: PHASE3 • Sponsor: Biocon Biologics UK Ltd • Aim: Disease control
Last updated Apr 26, 2026 20:02 UTC